Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Neovate Capital Partners is a venture capital firm founded to focus on early-stage life sciences investments. Established in the United States, the firm specializes in transformational medical devices and category-defining therapeutics at critical pre-inflection points. Neovate Capital Partners is headquartered in Pittsburgh, Pennsylvania, and has made total investments exceeding $150 million across prior funds and individual positions.
The firm has a strong emphasis on interventional solutions that redefine care paradigms, particularly in the biotech and healthcare sectors. Neovate Capital Partners has a notable track record of successful exits, including Small Bone Innovations, Scient'x, and Synthes, which collectively represent over $22 billion in exit value. The firm is actively involved in the Pennsylvania life sciences ecosystem, evidenced by its recent $2 million grant from the Ben Franklin Technology Development Authority in 2025.
Neovate Capital Partners invests primarily in early-stage life sciences, specifically targeting pre-seed, seed, and seed+ (extension) stages. The firm focuses on interventional solutions that drive new paradigms in care, including neuromodulation, tissue regeneration, and robotic and AI-enabled systems. Their investment strategy emphasizes identifying and strategically investing in breakthrough technologies before they gain widespread consensus.
The firm seeks opportunities at critical pre-inflection points, where their deep expertise across all life sciences segments can be leveraged to identify high-potential investments. Neovate Capital Partners is particularly interested in transformational medical devices and category-defining therapeutics, aiming for exits with a potential value exceeding $250 million within a sub-five-year timeframe.
Neovate Capital Partners has a focused portfolio that includes notable companies in the life sciences sector. One of their standout investments is Biorez, a regenerative medicine startup that developed a tendon/ligament healing implant. This company was acquired by ConMed in 2022 for $250 million, highlighting the firm's ability to identify high-value opportunities.
While specific current portfolio companies beyond Biorez are not disclosed, the firm has collectively invested over $150 million across various prior funds and individual positions in dozens of tech and life sciences startups. Their investment strategy is centered on transformational MedTech solutions that unlock significant acquirer value, particularly in the biotech and healthcare sectors.
Nick Pachuda, D.P.M. - Partner. Dr. Pachuda has extensive experience in the life sciences sector and is known for his expertise in musculoskeletal devices. He has been a speaker at the Musculoskeletal New Ventures Conference, showcasing his thought leadership in the field.
Kevin Rocco, M.S. - Partner. Rocco brings a strong background in life sciences investments and has been involved in various successful funding rounds within the sector.
Mike Green - Partner. Green is a co-founder of Neovate Capital Partners and has a significant track record in identifying high-potential investment opportunities in the life sciences.
Matt Harbaugh, J.D./M.B.A. - Partner. Harbaugh combines legal and business expertise, providing valuable insights into the regulatory landscape affecting life sciences investments.
To pitch Neovate Capital Partners, founders should visit their website at neovate.vc. The pitch deck should include a comprehensive overview of the startup's technology, market opportunity, competitive landscape, and team qualifications. Neovate Capital Partners prefers detailed presentations that clearly outline the startup's vision and potential impact in the life sciences sector.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are encouraged, as they can facilitate the review process.
In 2025, Neovate Capital Partners received a $2 million grant from Pennsylvania's Ben Franklin Technology Development Authority as part of the Shapiro Administration's life sciences initiative. This funding underscores the firm's active role in supporting early-stage life science technology companies in Pennsylvania.
Additionally, Neovate Capital Partners has highlighted its successful exit with Biorez, a regenerative medicine startup acquired by ConMed in 2022 for $250 million. This acquisition exemplifies the firm's ability to identify and nurture high-value opportunities in the life sciences sector.
What are Neovate Capital Partners' investment criteria?
Neovate Capital Partners focuses on early-stage life sciences investments, particularly in transformational medical devices and category-defining therapeutics. They target pre-seed, seed, and seed+ stages, emphasizing interventional solutions that redefine care paradigms.
How can I pitch to Neovate Capital Partners?
Founders can submit pitches through the firm's website at neovate.vc. It is recommended to include a detailed overview of the technology, market potential, and team background in the pitch deck.
What makes Neovate Capital Partners different from other VC firms?
Neovate Capital Partners distinguishes itself through its deep expertise in life sciences and a focus on identifying breakthrough technologies at critical pre-inflection points. Their track record includes significant exits in the medical device sector, which enhances their credibility and network within the industry.
What is the geographic scope of Neovate Capital Partners?
The firm primarily invests in the United States, with a strong emphasis on opportunities within Pennsylvania's life sciences ecosystem.
What is the typical check size for investments?
While specific check sizes are not disclosed, Neovate Capital Partners focuses on seed and Series A stages, indicating that their investments are likely to be in the range typical for these stages, often between $500,000 to $2 million.
What is Neovate Capital Partners' post-investment involvement?
The firm adds value through deep industry expertise, strategic guidance, and a focus on transformational technologies. They actively support portfolio companies in navigating growth and achieving successful exits.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.